Retatrutide Dosage Guide: What the Research Shows

Retatrutide Dosage: Evidence from Clinical Trials

One of the most common questions in the peptide research community concerns appropriate retatrutide dosing protocols. As retatrutide remains under clinical investigation, dosing information comes primarily from Phase 2 trial data published in peer-reviewed journals. This guide summarises the available evidence to help researchers understand the dosing landscape.

Important note: Retatrutide is a research compound that has not received regulatory approval for clinical use. The information presented here is derived from published clinical trial data and is intended for educational and research purposes only.

Phase 2 Trial Dosing Protocol

The pivotal Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, evaluated multiple dose levels in adults with obesity (BMI ≥30 or ≥27 with comorbidities). The trial explored the following dose groups:

• 1 mg weekly (maintenance dose, no escalation)
• 4 mg weekly (escalated from starting dose)
• 8 mg weekly (escalated from starting dose)
• 12 mg weekly (escalated from starting dose)
• Placebo (control group)

Dose Escalation Schedule

Participants in the higher-dose groups did not begin at their target dose. Instead, the trial employed a gradual dose escalation protocol designed to minimise gastrointestinal side effects:

• Weeks 1-4: Starting dose (typically 2 mg)
• Weeks 5-8: Intermediate dose increase
• Weeks 9-12: Further escalation towards target
• Weeks 13+: Maintenance at target dose

This gradual approach is consistent with other GLP-1-class peptides and is specifically designed to allow the body to acclimate, reducing the incidence and severity of nausea and other gastrointestinal effects.

Dose-Response Relationship

The trial data demonstrated a clear dose-dependent response, with higher doses producing greater weight reduction:

Weight Loss by Dose at 48 Weeks

• 1 mg: approximately 8.7% body weight reduction
• 4 mg: approximately 17.1% body weight reduction
• 8 mg: approximately 22.8% body weight reduction
• 12 mg: approximately 24.2% body weight reduction
• Placebo: approximately 2.1% body weight reduction

Notably, even the lowest active dose (1 mg) produced significantly greater weight loss than placebo, demonstrating the potency of the triple agonist mechanism even at conservative doses.

Administration Method

Retatrutide is administered via subcutaneous injection once weekly. In clinical trials, injections were typically given in the abdomen, thigh, or upper arm. The once-weekly schedule reflects the compound’s extended half-life, achieved through molecular modifications that slow metabolic clearance.

Key Administration Considerations (from Trial Protocols)

• Injections were administered at the same time each week for consistency
• Rotation of injection sites was recommended to avoid local tissue reactions
• Reconstitution protocols varied by formulation (lyophilised vs. pre-mixed)
• Proper cold-chain storage was maintained until use

Side Effects by Dose Level

Understanding the relationship between dosage and side effects is critical for research planning:

Gastrointestinal Effects

The most common side effects across all dose levels were gastrointestinal in nature. Their frequency increased with dose but was most pronounced during escalation periods:

• Nausea: reported in 16-45% of participants (dose-dependent), predominantly during the first 4-8 weeks
• Diarrhoea: reported in 10-25% of participants
• Vomiting: reported in 5-15% of participants, almost exclusively during dose escalation
• Decreased appetite: reported in 10-30% of participants (considered both a side effect and intended mechanism)

Serious Adverse Events

Serious adverse events were rare across all dose groups and occurred at similar rates to placebo. No deaths were attributed to retatrutide in the Phase 2 trial.

Storage and Handling for Research

Proper storage is essential for maintaining peptide integrity and ensuring accurate research results:

• Lyophilised (powder): Store at -20°C to 4°C. Protected from light. Stable for extended periods when properly stored.
• Reconstituted: Store at 2-8°C (refrigerated). Use within 28 days. Do not freeze reconstituted peptide.
• Reconstitution medium: Bacteriostatic water (BAC water) is standard for research applications.

Ongoing Phase 3 Research

Eli Lilly’s Phase 3 clinical programme for retatrutide includes multiple large-scale trials examining:

• Long-term efficacy and safety (up to 2 years)
• Optimal dosing strategies for different patient populations
• Effects on specific conditions including NAFLD/NASH
• Cardiovascular outcomes
• Potential for combination with other therapeutic approaches

Results from these trials will provide more definitive dosing guidance and are expected to inform regulatory submissions.

Sourcing Research-Grade Retatrutide

For researchers requiring high-purity retatrutide, proper sourcing is critical. RetaExpress offers research-grade retatrutide in multiple vial sizes (5mg, 10mg, 15mg, 20mg, 30mg), with certificates of analysis and third-party purity testing.

All products are shipped from Canada with appropriate temperature-controlled packaging to maintain compound stability during transit.